著者検索結果

1

Chronic Lung Disease after Premature Birth 著者: Vivek Subbiah

出版事項 2008

全文の入手
Carta

お気に入りに追加

保存先:
2

The next generation of evidence-based medicine 著者: Vivek Subbiah

出版事項 2023

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
3

Tissue-agnostic cancer therapies: promise, reality, and the path forward 著者: Vivek Subbiah

出版事項 2025

全文の入手
Artigo

お気に入りに追加

保存先:
4

Challenging Standard-of-Care Paradigms in the Precision Oncology Era 著者: Vivek Subbiah, Razelle Kurzrock

出版事項 2018

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
5

Managing Cancer Care during the COVID-19 Pandemic and Beyond 著者: Omar Alhalabi, Vivek Subbiah

出版事項 2020

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
6

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis 著者: Vivek Subbiah, Razelle Kurzrock

出版事項 2023

全文の入手
Artigo

お気に入りに追加

保存先:
7

Tumor-agnostic drug development in dMMR/MSI-H solid tumors 著者: Deepak Bhamidipati, Vivek Subbiah

出版事項 2023

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
8

Clinical development and management of adverse events associated with FGFR inhibitors 著者: Vivek Subbiah, Srđan Verstovšek

出版事項 2023

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
9

Advances in Targeting RET-Dependent Cancers 著者: Vivek Subbiah, Gilbert J. Cote

出版事項 2020

全文の入手
Revisão

お気に入りに追加

保存先:
10

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy 著者: Mohamed A. Gouda, Vivek Subbiah

出版事項 2023

全文の入手
Revisão

お気に入りに追加

保存先:
11

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors 著者: Mohamed A. Gouda, Vivek Subbiah

出版事項 2023

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
12

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers 著者: Mohamed A. Gouda, Vivek Subbiah

出版事項 2023

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
13

Clinical Development of BRAF plus MEK Inhibitor Combinations 著者: Vivek Subbiah, Christina S. Baik, John M. Kirkwood

出版事項 2020

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
14

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm 著者: Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

出版事項 2020

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
15

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives 著者: Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

出版事項 2017

全文の入手全文の入手
Artigo

お気に入りに追加

保存先:
16

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians 著者: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

出版事項 2020

全文の入手
Editorial

お気に入りに追加

保存先:
17

State-of-the-Art Strategies for Targeting RET-Dependent Cancers 著者: Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

出版事項 2020

全文の入手
Revisão

お気に入りに追加

保存先:
18

The abscopal effect in patients with cancer receiving immunotherapy 著者: Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

出版事項 2023

全文の入手全文の入手
Revisão

お気に入りに追加

保存先:
19

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? 著者: Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

出版事項 2025

全文の入手
Revisão

お気に入りに追加

保存先:
20

The emerging role of PI3K inhibitors for solid tumour treatment and beyond 著者: Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

出版事項 2023

全文の入手
Revisão

お気に入りに追加

保存先:

Chronic Lung Disease after Premature Birth 著者: Vivek Subbiah

The next generation of evidence-based medicine 著者: Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward 著者: Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era 著者: Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond 著者: Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> 著者: Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors 著者: Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors 著者: Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers 著者: Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy 著者: Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors 著者: Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers 著者: Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations 著者: Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm 著者: Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives 著者: Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians 著者: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers 著者: Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy 著者: Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? 著者: Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond 著者: Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

検索結果 - Vivek Subbiah

Chronic Lung Disease after Premature Birth 著者: Vivek Subbiah

The next generation of evidence-based medicine 著者: Vivek Subbiah

Tissue-agnostic cancer therapies: promise, reality, and the path forward 著者: Vivek Subbiah

Challenging Standard-of-Care Paradigms in the Precision Oncology Era 著者: Vivek Subbiah, Razelle Kurzrock

Managing Cancer Care during the COVID-19 Pandemic and Beyond 著者: Omar Alhalabi, Vivek Subbiah

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: <i>Genomics Is the Diagnosis</i> 著者: Vivek Subbiah, Razelle Kurzrock

Tumor-agnostic drug development in dMMR/MSI-H solid tumors 著者: Deepak Bhamidipati, Vivek Subbiah

Clinical development and management of adverse events associated with FGFR inhibitors 著者: Vivek Subbiah, Srđan Verstovšek

Advances in Targeting RET-Dependent Cancers 著者: Vivek Subbiah, Gilbert J. Cote

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy 著者: Mohamed A. Gouda, Vivek Subbiah

Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for <i>BRAF</i> V600E–Positive Adult and Pediatric Solid Tumors 著者: Mohamed A. Gouda, Vivek Subbiah

Precision oncology with selective RET inhibitor selpercatinib in <i>RET</i>-rearranged cancers 著者: Mohamed A. Gouda, Vivek Subbiah

Clinical Development of BRAF plus MEK Inhibitor Combinations 著者: Vivek Subbiah, Christina S. Baik, John M. Kirkwood

From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm 著者: Jacob J. Adashek, Vivek Subbiah, Razelle Kurzrock

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives 著者: Vivek Subbiah, Hubert H. Chuang, Dhiraj Gambhire, Kalevi Kairemo

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians 著者: Vivek Subbiah, David B. Solit, Timothy A. Chan, Razelle Kurzrock

State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers 著者: Vivek Subbiah, Dong Yang, Vamsidhar Velcheti, Alexander Drilon, Funda Meric‐Bernstam

The abscopal effect in patients with cancer receiving immunotherapy 著者: Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies? 著者: Denis Horgan, Paul Hofman, Daniel J. Schneider, Umberto Malapelle, Vivek Subbiah

The emerging role of PI3K inhibitors for solid tumour treatment and beyond 著者: Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah, Giuseppe Curigliano

検索ツール:

関連主題